LimmaTech Biologics

LimmaTech Biologics is a clinical-stage biotech focused on addressing the global antimicrobial resistance (AMR) crisis through novel vaccine development. The company utilizes a proprietary, self-adjuvanting, multivalent vaccine platform based on engineered E. coli to efficiently produce complex carbohydrate and protein vaccine candidates. Backed by leading investment funds and a team with decades of vaccine development experience, LimmaTech is rapidly expanding its pipeline to prevent infections caused by drug-resistant pathogens. Its mission is to deliver affordable, effective vaccines as a critical strategy to avert disease and reduce the threat of AMR.

Proprietary multivalent, self-adjuvanting vaccine platform based on engineered E. coli that produces complex carbohydrate and protein vaccine candidates in a single, scalable production step.

The competitive landscape for vaccines against AMR pathogens is developing, with several large pharma companies and biotechs exploring various approaches. LimmaTech differentiates itself with a proprietary, efficient E. coli-based production platform designed for multivalent, self-adjuvanting candidates, aiming for cost-effective scalability.